Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 2/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CETP | P11597 | 3/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.31 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.31 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1764273 | 1.00 | PDPK1 (0.44) | PDPK1MTORTSHRFUCA1ALDH1A1 | |
| SCHEMBL9706806 | 0.87 | PDPK1 (0.52) | PDPK1MTORTSHRFUCA1CETP | |
| SCHEMBL9706801 | 0.87 | PDPK1 (0.52) | PDPK1MTORTSHRFUCA1CETP | |
| SCHEMBL13274591 | 0.78 | PDPK1 (0.43) | PDPK1MTORTSHRALDH1A1CETP | |
| SCHEMBL1763811 | 0.78 | PDPK1 (0.43) | PDPK1MTORTSHRALDH1A1CETP | |
| SCHEMBL23563202 | 0.76 | ALDH1A1 (0.39) | PDPK1MTORTSHRFUCA1ALDH1A1 | |
| SCHEMBL9300189 | 0.76 | ALDH1A1 (0.39) | PDPK1MTORTSHRFUCA1ALDH1A1 | |
| SCHEMBL9706851 | 0.76 | ALDH1A1 (0.39) | PDPK1MTORTSHRFUCA1ALDH1A1 | |
| SCHEMBL14268497 | 0.76 | ALDH1A1 (0.39) | PDPK1MTORTSHRFUCA1ALDH1A1 | |
| SCHEMBL9299791 | 0.76 | PDPK1 (0.65) | PDPK1MTORTSHRALDH1A1CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618269-B2 | Glycorandomization and production of novel novobiocin analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-12-31 | — | — | US | disclosed |
| US-20120264924-A1 | Glycorandomization and Production of Novel Novobiocin Analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-10-18 | — | — | US | disclosed |
| US-20080268504-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264924-A1 | Glycorandomization and Production of Novel Novobiocin Analogs | NMT2, NMT1, NAMPT | PDPK1 2809/4885MTOR 3668/4885TSHR 3900/4885 |
| US-20080268504-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | NMT1, NMT2, B3GNT2 | PDPK1 2037/4885MTOR 1888/4885TSHR 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.